Key facts
- EarlySight’s last known valuation is $41.2M (Sep 2025).
- It has raised $15.0M; the latest was Seed Round ($11.4M) in Sep 2025.
- Notable investors include MassChallenge, Venture Kick, Ecole Polytechnique Federale de Lausanne, Verve Ventures, Zürcher Kantonalbank — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for EarlySight
- ·The full record, as it builds
Funding rounds
No funding rounds for EarlySight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EarlySight
Developer of a medical device designed to help doctors detect and treat eye diseases. The company's device uses cellular-level imaging technology that detects minor structural changes of the retina, and transscleral illumination allows the monitoring of day-to-day effects of treatment in a non-invasive manner, enabling eye specialists to visualize the morphology of numerous cells in the retina.
- Sector
- Healthcare
- HQ
- Geneva, Switzerland
- Founded
- 2019
- Employees
- 9
- Website
- earlysight.com/
- Ownership
- Privately Held (backing)
EarlySight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EarlySight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EarlySight in its N-PORT filings yet. We sweep new filings monthly.